Literature DB >> 8077363

Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.

R Schreck1, F Schnieders, C Schmutzler, J Köhrle.   

Abstract

Iodothyronine 5'-deiodinase isoenzymes generate the thyroid hormone 3,3',5-triiodothyronine from the prohormone L-T4. Basal and retinoic acid (RA)-induced type I 5'-deiodinase (5'DI) activities were studied in human thyroid carcinoma cell lines. In the follicular thyroid carcinoma line FTC-133, nanomolar concentrations of 9-cis, 13-cis-, and all-trans-RA induced 5'DI activity. Kinetics with all-trans-RA revealed 5'DI stimulation after 1 day and a maximal effect after 3 days. Increased abundance of the p27 5'DI subunit was demonstrated after RA treatment by N-bromoacetyl-[125I]T4 affinity labeling. Actinomycin-D and cycloheximide blocked RA-mediated induction. RA stimulated 5'DI activity to a lesser extent in FTC-238 cells, whereas neither basal 5'DI activity nor stimulation by RA was found in anaplastic thyroid carcinoma, human lung, or leukemia cell lines. Steady state messenger ribonucleic acid levels of RA receptor-alpha and -beta were increased after incubation of FTC-133 cells with all-trans-RA. The high 5'DI activity of differentiated rat thyroid FRTL-5 cells was not further induced by RA. Butyrate did not alter 5'DI, but increased the activity of the differentiation marker alkaline phosphatase in FTC-133 and FTC-238 cells. T4 and T3 had no effect on basal or RA-stimulated 5'DI activity. These data suggest that expression and retinoid induction of 5'DI may serve as a sensitive and functional differentiation parameter of follicular thyroid carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077363     DOI: 10.1210/jcem.79.3.8077363

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  The selenoenzyme family of deiodinase isozymes controls local thyroid hormone availability.

Authors:  J Köhrle
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 2.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

Review 3.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

Review 4.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

5.  Type I 5'-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma.

Authors:  J Pachucki; M Ambroziak; Z Tanski; J Luczak; J Nauman; A Nauman
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

6.  Differential selenium-dependent expression of type I 5'-deiodinase and glutathione peroxidase in the porcine epithelial kidney cell line LLC-PK1.

Authors:  M Gross; M Oertel; J Köhrle
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

7.  Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma.

Authors:  S Mendes Coelho; R Corbo; A Buescu; D P Carvalho; M Vaisman
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

8.  Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro.

Authors:  L Lan; D Cui; Y Luo; B Y Shi; L L Deng; G Y Zhang; H Wang
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

9.  The enzymatic activity of type 1 iodothyronine deiodinase (D1) is low in liver hemangioma: a preliminary study.

Authors:  Oskar Kornasiewicz; Marcin Debski; Marta Stepnowska; Anna Szałas; Ewa Bar-Andziak; Marek Krawczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-01-05       Impact factor: 4.291

10.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.